chr7-81959325-G-C
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_000722.4(CACNA2D1):c.3109C>G(p.Gln1037Glu) variant causes a missense change. The variant allele was found at a frequency of 0.0000366 in 1,611,280 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000722.4 missense
Scores
Clinical Significance
Conservation
Publications
- short QT syndromeInheritance: AD Classification: SUPPORTIVE, NO_KNOWN Submitted by: ClinGen, Orphanet
- Brugada syndromeInheritance: AD, Unknown Classification: LIMITED, NO_KNOWN Submitted by: Ambry Genetics, Genomics England PanelApp
- genetic developmental and epileptic encephalopathyInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- developmental and epileptic encephalopathy 110Inheritance: AR Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae), G2P
- Brugada syndrome 1Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CACNA2D1 | ENST00000356860.8 | c.3109C>G | p.Gln1037Glu | missense_variant | Exon 38 of 39 | 1 | NM_000722.4 | ENSP00000349320.3 | ||
| CACNA2D1 | ENST00000443883.2 | c.3145C>G | p.Gln1049Glu | missense_variant | Exon 38 of 39 | 5 | ENSP00000409374.2 | |||
| CACNA2D1 | ENST00000705962.1 | c.2989C>G | p.Gln997Glu | missense_variant | Exon 37 of 38 | ENSP00000516190.1 | ||||
| CACNA2D1 | ENST00000705961.1 | c.2875C>G | p.Gln959Glu | missense_variant | Exon 36 of 37 | ENSP00000516189.1 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 151980Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000797 AC: 2AN: 250804 AF XY: 0.00000738 show subpopulations
GnomAD4 exome AF: 0.0000397 AC: 58AN: 1459300Hom.: 0 Cov.: 30 AF XY: 0.0000289 AC XY: 21AN XY: 726118 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
Age Distribution
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151980Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74208 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Brugada syndrome Uncertain:1
This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 1037 of the CACNA2D1 protein (p.Gln1037Glu). This variant is present in population databases (rs748929082, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with CACNA2D1-related conditions. ClinVar contains an entry for this variant (Variation ID: 580922). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The p.Q1037E variant (also known as c.3109C>G), located in coding exon 38 of the CACNA2D1 gene, results from a C to G substitution at nucleotide position 3109. The glutamine at codon 1037 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at